Archive for the 'Alzheimers' Category

Roskamp Institute Supports Moves for Greater State Funding of Biotech Research

Roskamp Institute Director Dr. Michael Mullan was one of many who represented the biotech industry at the Biotechnology Legislative Caucus yesterday to request more state funding in helping the industry thrive in the state. This is important to Florida this would help the state diversify its economy more, and many organizations within the state have active projects. For instance, the institute is testing Nilvadipine, an experimental drug aimed at treating early-onset Alzheimer’s disease, and has other projects.

You can read more about the Biotechnology Legislative Caucus in the Tallahasee Democrat‘s article “Florida biotech industry leaders call for ‘next step’” and Bradenton Herald‘s “Biotech touted as key to future,” both of which were published today.

The Roskamp Insitute website also has more information.


Roskamp Institute Looking for Alzheimer’s Clinical Trial Participants

As reported in today’s Bradenton Herald, the Roskamp Institute is searching for clinical trial participants for two potential Alzheimer’s disease treatments. Bapineuzumab and ELND005 are being tested; both hope to successfully remove plaque from the brain which helps cause the condition. For more information please visit the Roskamp Institute Clinical Trial Division web page.

The Roskamp Institute Plans Alzheimer’s Treatment Trial

The Sarasota Herald-Tribune reports today in an article titled “In quest to unravel Alzheimer’s, drug may soon be tested locally” that The Roskamp Institute is planning to conduct a clinical trial of a potential Alzheimer’s disease treatment this summer. It will occur in the Sarasota, Florida area, where the Institute is located.

Roskamp Institute Will Host Neuroscience Doctorate Research Program

The Roskamp Institute announced today that it will host a neuroscience doctorate research program as part of The Open University’s — of Milton Keynes, England — Affiliated Research Centre. This is the first program of this kind in Florida and will help students prepare better for researching Alzheimer’s disease and related disorders as they work with world-class scientists at The Roskamp Institute.

For more information, see the press release “Roskamp Institute Opens its Doors to Neuroscience Doctorate Research Program” at

Roskamp Institute Alzheimer’s Research Validated by Independent Japanese Study

The Roskamp Institute announced on December 14, 2007 that an independent Tokyo Medical University study validates its ongoing research into the Alzheimer’s Disease drug Nilvadipine which is in testing. The International Journal of Geriatric Psychiatry details the results of study that suggests that Nilvadipine can prevent in people with memory problems the onset of Alzheimer’s.

For more information about this study and the Roskamp Institute, please contact Sarah Bascom or Kristen Bridges at (850) 222-2140 or

Roskamp Institute Receives Award of Appreciation

On December 6, 2007 the Economic Development Council (EDC) of the Manatee Chamber of Commerce presented the Roskamp Institute with the 2007 Innovation and Technology Award. The EDC honored the Institute since it has made meaningful contributions to scientific research as it studies neuropsychiatric and neurodegenerative conditions, especially Alzheimer’s Disease.

The Roskamp Institute and EDC will work together in 2008 to foster a better environment for bio-tech companies in the county.

Roskamp Institute Studying Potential Usefulness of Beta-amyloid in Treating Alzheimer’s

The Roskamp Institute is currently determining whether beta-amyloid, a protein, is useful in the screening of individuals who are at risk of developing Alzheimer’s Disease and monitoring how current sufferers are responding to treatments. Scientists at the Institute have published their scientific findings that indicate that beta-amyloid could serve as an important biomarker for the disease in the “The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels” article for the journal Neuroscience Letters.

Visit Roskamp Institute’s press release about these developments for more information.